TCR2 Therapeutics Inc
NASDAQ:TCRR
Income Statement
Earnings Waterfall
TCR2 Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-131.4m
USD
|
Operating Income
|
-131.4m
USD
|
Other Expenses
|
-31.7m
USD
|
Net Income
|
-163.1m
USD
|
Income Statement
TCR2 Therapeutics Inc
Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Operating Income | ||||||||||||||||||||
Operating Expenses |
(22)
|
(26)
|
(33)
|
(38)
|
(46)
|
(51)
|
(57)
|
(61)
|
(64)
|
(69)
|
(74)
|
(82)
|
(91)
|
(100)
|
(107)
|
(114)
|
(119)
|
(123)
|
(131)
|
|
Selling, General & Administrative |
(6)
|
(7)
|
(8)
|
(10)
|
(12)
|
(14)
|
(15)
|
(16)
|
(17)
|
(17)
|
(18)
|
(20)
|
(22)
|
(23)
|
(23)
|
(23)
|
(24)
|
(24)
|
(26)
|
|
Research & Development |
(16)
|
(20)
|
(25)
|
(28)
|
(34)
|
(37)
|
(42)
|
(46)
|
(47)
|
(52)
|
(56)
|
(62)
|
(69)
|
(77)
|
(84)
|
(91)
|
(95)
|
(98)
|
(105)
|
|
Operating Income |
(22)
N/A
|
(26)
-20%
|
(33)
-25%
|
(38)
-16%
|
(46)
-20%
|
(51)
-11%
|
(57)
-11%
|
(61)
-8%
|
(64)
-4%
|
(69)
-8%
|
(74)
-8%
|
(82)
-10%
|
(91)
-11%
|
(100)
-10%
|
(107)
-7%
|
(114)
-7%
|
(119)
-4%
|
(123)
-3%
|
(131)
-7%
|
|
Pre-Tax Income | ||||||||||||||||||||
Interest Income Expense |
1
|
2
|
3
|
3
|
4
|
4
|
4
|
3
|
2
|
2
|
1
|
1
|
0
|
0
|
0
|
0
|
1
|
2
|
3
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
(31)
|
(34)
|
|
Pre-Tax Income |
(21)
N/A
|
(24)
-18%
|
(30)
-24%
|
(35)
-16%
|
(42)
-21%
|
(48)
-12%
|
(53)
-12%
|
(58)
-10%
|
(61)
-5%
|
(67)
-9%
|
(73)
-9%
|
(81)
-11%
|
(90)
-11%
|
(100)
-10%
|
(107)
-8%
|
(114)
-7%
|
(119)
-4%
|
(152)
-28%
|
(163)
-7%
|
|
Net Income | ||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
Income from Continuing Operations |
(21)
|
(24)
|
(30)
|
(35)
|
(42)
|
(48)
|
(53)
|
(58)
|
(62)
|
(67)
|
(73)
|
(81)
|
(91)
|
(100)
|
(107)
|
(115)
|
(119)
|
(152)
|
(163)
|
|
Net Income (Common) |
(55)
N/A
|
(62)
-13%
|
(107)
-73%
|
(100)
+6%
|
(96)
+4%
|
(98)
-1%
|
(53)
+45%
|
(58)
-10%
|
(62)
-5%
|
(67)
-9%
|
(73)
-9%
|
(81)
-11%
|
(91)
-11%
|
(100)
-10%
|
(107)
-8%
|
(115)
-7%
|
(119)
-4%
|
(152)
-28%
|
(163)
-7%
|
|
EPS (Diluted) |
-2.52
N/A
|
-2.35
+7%
|
-4.44
-89%
|
-4.2
+5%
|
-4.02
+4%
|
-4.07
-1%
|
-2.22
+45%
|
-2.43
-9%
|
-2.02
+17%
|
-2
+1%
|
-1.97
+2%
|
-2.12
-8%
|
-2.36
-11%
|
-2.6
-10%
|
-2.8
-8%
|
-2.99
-7%
|
-3.09
-3%
|
-3.93
-27%
|
-4.15
-6%
|